Table 6 Predicted molecular interactions and binding energies (\(\Delta\)G) of SLA-1*04:01 and TLR4 complexes.

From: Immunoinformatics-guided approach for designing a pan-proteome multi-epitope subunit vaccine against African swine fever virus

Complex

Molecular interactions

\(\Delta\)G (kcal/mol)

SLA1*04:01-TVSAIELEY

13 HB, 130 NBC

−12.1

SLA1*04:01-KTRDFFILY

11 HB, 142 NBC

−12.1

SLA1*04:01-MMDFERVHY

9 HB, 108 NBC

−11.3

SLA1*04:01-KNLSIIWEY

12 HB, 156 NBC

−11.8

SLA1*04:01-KAIELYWVF

8 HB, 116 NBC

−11.6

SLA1*04:01-YLYEIEIEY

10 HB, 129 NBC

−11.3

SLA1*04:01-NSDTVGWSW\(^{\rm a}\)

11 HB, 120 NBC

−10.8

SLA1*04:01-ATAAATEAY\(^{ \rm b}\)

14 HB, 142 NBC

−11.2

TLR4-ASFV construct

6 SB, 15 HB, 199 NBC

−14.0

TLR4-Brucella lumazine synthase\(^{\rm c}\)

7 SB, 15 HB, 257 NBC

−9.9

TLR4-M. tuberculosis RpfE\(^{\rm d}\)

6 SB, 31 HB, 262 NBC

−9.7

TLR4-S. pneumoniae DnaJ\(^{\rm e}\)

4 SB, 18 HB, 156 NBC

−13.1

  1. HB hydrogen bonds, NBC non-bonded contacts, SB salt bridges.
  2. Control: \(^{\rm a}\)influenza-derived epitope from RCSB ID: 3QQ3 and \(^{\rm b}\)ebola-derived epitope from RCSB ID: 3QQ4, both bound to SLA1*0401 in crystal structures. \(^{\rm{c-e}}\)TLR4-agonists.